Caliper and Seegene partner to provide multiplex molecular
31 Jan 2011
Caliper Life Sciences, Inc. and Seegene, Inc.
have entered into a
strategic partnership to enable Seegene's SeePlex multiplex diagnostic
assays to run on Caliper's innovative LabChip Dx platform.
assays will be marketed and distributed outside of the United States in
a preferred partnership for use with the LabChip Dx through Seegene's
extensive network of global distributors.
The parties will co-market Caliper's LabChip Dx platform and Seegene's complete line of unique
multiplex diagnostic content effective immediately, and work together to
implement specific content and platform technology development efforts
to expand the number of diagnostic tests available, which will be
offered in a unique, co-branded product brochure.
Seegene and Caliper
intend to work together to commercialize selected diagnostic assays with
improved sensitivity and specificity while reducing overall costs.
The LabChip Dx system, which includes specific diagnostic
identification, scoring and reporting software, developed in
collaboration with Seegene, is based on the same approach that has
become the standard, microfluidic based, electrophoretic separation
platform in life sciences research, enabling high throughput,
multiplex, cost effective sample processing for discovery and
validation of molecular and companion diagnostics.
The platform can
analyze large numbers of multiplex samples using very minimal volume
of sample with automatic pipetting and avoids the need to further
purify or dilute diagnostic PCR products. The cost-effective
approach of Caliper's robust microfluidics technology explains its
high rate of adoption among research laboratories around the world.
Seegene's proprietary technologies and products have been shown
in roughly 500 publications and posters to deliver more accurate and
cost effective results in diagnostic testing, a huge benefit for
clinical testing laboratories, where accuracy and speed are
Seegene's Dual Priming Oligonucleotide (DPO) approach to
PCR-based assays uses a new technique for DNA priming which is
structurally and functionally different from traditional PCR
priming. Seegene has successfully validated a wide variety of assays
utilizing DPO technology in various markets around the world.
"Caliper continues to develop innovative microfluidic solutions
that uniquely enable molecular and companion diagnostics," said
Kevin Hrusovsky, President and CEO of Caliper Life Sciences. "This
agreement to partner with Seegene's innovative multiplex diagnostic
content on the LabChip Dx platform should dramatically improve the
economics of diagnostic testing and pave the way for the development
of critical diagnostics to accelerate the worldwide implementation
of personalized medicine.
"We believe that Seegene's DPO technology
uniquely enables sensitive and specific, highly multiplexed assays
directly from clinical samples, significantly improving the
economics of today for centralized and hospital based diagnostic
"We are pleased to partner with Caliper for developing new and
highly innovative molecular and companion diagnostic products," said
Jong-Yoon Chun, Seegene Founder and CEO. "Our unique SeePlex
technology enables highly multiplexed PCR directly from clinical
samples. When coupled with Caliper's microfludics based
electrophoretic LabChip platforms, the SeePlex assays enable new
paradigms for a variety of analytes in a fully automated and highly
cost effective manner.
"We believe our partnership to commercialize
on Caliper's LabChip Dx platform should provide the most competitive
and cost effective approach to diagnosing and managing a variety of
threats to public health, thus contributing to the improvement of